MADRID, 21 Mar. (EUROPA PRESS) –
Grifols shares soared almost 4% this Thursday on the stock market around 9:45 a.m., in a context marked by the movements of bearish funds and by the wait for the analysis of the information required from the blood products company by the National Commission of the Stock Market (CNMV) after the crisis unleashed by the report published by Gotham City Research.
Thus, Grifols led the rise of the Ibex 35 with a rise of 3.65%, until exchanging its shares at a price of 8.354 euros, after having started the session with a rise of 2.13%, with its shares at 8.232 euros .
So far this year, the Catalan company, which this Thursday updated the financial report of its accounts at the CNMV after the KPMG audit, has recorded an accumulated depreciation of 46.24%, while the market capitalization has situated slightly above 5,000 million euros.
Specifically, Grifols has added complementary information to the accounts document previously published on February 29, without the ‘approval’ of KPMG, but emphasizes that it was already communicated to the supervisor on March 8.
On a purely financial level, the blood products firm explained that it had decided to further detail the pre-existing agreement with ImmunoTek, aligning the accounting treatment with the essence of the contract, which was last modified in June 2023.
Thus, company sources explained to Europa Press that this integration did not affect the profit and loss account nor did it have a “material impact” on key metrics, including the leverage ratio, which stands at 6.3 times, nor on the statement of cash flows, where it shows a positive impact of 4 million euros.
Specifically, Grifols’ total assets, including ImmunoTek and already with the audited accounts, reach 21,441 million euros, compared to the 21,326 million euros that were reported in the accounts of February 29, which shows a difference of 115 million, of which 96 million euros correspond to non-current assets.
The president of the CNMV, Rodrigo Buenaventura, announced this Wednesday that the report on Grifols “could be known shortly”, stressing that they hope to conclude their analysis “very soon” and, when this occurs, they will report in a timely manner.
These statements represent a temporary advance with respect to the last ones made in that sense on the same matter, since at the beginning of the month he limited himself to pointing out that Grifols’ analysis still had “weeks” left to conclude.
Likewise, Buenaventura highlighted at the end of February that they had requested new clarifications and complementary information from the Catalan blood products company and that, therefore, they needed more time to conclude their investigation.
“We just received them a few days ago and we still need a few more weeks,” explained Buenaventura during the press conference held then in relation to the presentation of the public organization’s activity plan for this year.
